弥漫性中线胶质瘤的蛋白质组学景观凸显非组蛋白甲基转移酶的治疗潜力
该研究对55例弥漫性中线胶质瘤(DMG)患者样本进行LC-MS3蛋白质组学分析及DNA甲基化和DNA/RNA测序,并对30例样本进行翻译后修饰分析。DMG整体蛋白甲基化水平高,非组蛋白甲基转移酶METTL13和METTL21B及激酶PAK2、PRKACA、AKT1是关键分子;METTL13敲低可减少EEF1A1蛋白甲基化、改变致癌蛋白合成并在体内外抑制DMG细胞生长。作者认为靶向非组蛋白甲基转移酶是有前景的治疗策略。
要点
- DMG整体蛋白甲基化水平高,翻译机器蛋白和凋亡调控因子显著富集。
- METTL13敲低减少EEF1A1蛋白甲基化、改变致癌蛋白合成并抑制DMG细胞生长。
- 作者认为靶向非组蛋白甲基转移酶是DMG有前景的治疗策略。
核心结论
- DMG依赖甲基化信号通路,尤其是METTL13调控EEF1A1蛋白甲基化和致癌蛋白合成。
- 靶向非组蛋白甲基转移酶为DMG提供了有前景的治疗策略。
- 翻译后修饰尤其是甲基化信号通路可能是DMG乃至其他目前不可治愈癌症的新治疗靶点。
研究设计与样本
- 对55例DMG患者样本进行LC-MS3蛋白质组学分析及DNA甲基化和DNA/RNA测序。
- 对30例患者样本进行翻译后修饰分析(磷酸化蛋白质组和甲基化蛋白质组)。
- 在体外和体内研究调控关键蛋白靶点对蛋白甲基化、蛋白合成和DMG细胞生长的影响。
主要发现
- DMG整体蛋白甲基化水平高,翻译机器蛋白和凋亡调控相关因子显著富集。
- DMG中关键激酶靶点高度磷酸化,但整体蛋白磷酸化水平低于正常脑组织。
- 非组蛋白甲基转移酶METTL13和METTL21B以及蛋白激酶PAK2、PRKACA和AKT1分别是DMG甲基化蛋白质组和磷酸化蛋白质组的关键分子。
- METTL13敲低导致EEF1A1蛋白甲基化减少、致癌蛋白合成改变,并在体外和体内抑制DMG细胞生长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diffuse midline glioma (DMG) is a highly aggressive pediatric brain tumor with limited treatment options despite extensive genomic characterization. The aim of this study was to investigate the proteomic landscape of DMG to identify potential therapeutic targets. METHODS: We conducted a comprehensive proteomic analysis using LC-MS3, along with DNA methylation and DNA/RNA sequencing in 55 DMG patients' samples. post-translational modification profiling (phosphoproteome and methylproteome) was conducted in 30 patient samples. We then investigated the effects of modulating key protein targets on protein methylation, protein synthesis, and DMG cell growth in vitro and in vivo. RESULTS: DMGs exhibited high global protein methylation, with significant enrichment of translation machinery proteins and factors involved in apoptosis regulation. Surprisingly, while targets of key kinases were highly phosphorylated, overall protein phosphorylation was lower in DMG compared to normal brain tissues. Non-histone methyltransferases METTL13 and METTL21B, along with protein kinases PAK2, PRKACA, and AKT1, were identified as key players in DMG methylproteome and phosphoproteome, respectively. METTL13 knockdown led to reduced EEF1A1 protein methylation, a shift in oncoprotein synthesis, and inhibited DMG cell growth in vitro and in vivo. CONCLUSIONS: Our findings highlight the dependency of DMG on methyl-signaling pathways, particularly involving METTL13, which regulates EEF1A1 protein methylation and oncoprotein synthesis. Targeting the non-histone methyltransferases offers a promising therapeutic strategy for DMG. This study underscores the potential of post-translational modifications, specifically methyl-signaling pathways, as novel therapeutic targets for DMG and possibly other currently incurable cancers.
引用
- Anguraj Vadivel AK, Pajovic S, Siddaway R, et al. The proteomic landscape of diffuse midline glioma highlights the therapeutic potential of non-histone protein methyltransferases. Neuro Oncol. 2025. PMID: 39954016. doi:10.1093/neuonc/noaf033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。